Abstract
Parkinson's disease (PD) occurs in approximately 1% of the population over 65 years of age and has become increasingly more common with advances in age. The number of individuals older than 60 years has been increasing in modern societies, as well as life expectancy in developing countries; therefore, PD may pose an impact on the economic, social, and health structures of these countries. Oxidative stress is highlighted as an important factor in the genesis of PD, involving several enzymes and signaling molecules in the underlying mechanisms of the disease. This review presents updated data on the involvement of oxidative stress in the disease, as well as the use of antioxidant supplements in its therapy.
Highlights
IntroductionParkinson’s disease (PD) is considered cosmopolitan and makes no distinction between social classes or between races, affecting both men and women, especially in the age range between 55 and 65 years, but it tends to occur with greater frequency in men [1, 2]
Parkinson’s disease (PD) is considered cosmopolitan and makes no distinction between social classes or between races, affecting both men and women, especially in the age range between 55 and 65 years, but it tends to occur with greater frequency in men [1, 2].It is estimated that this disorder affects approximately 1% of the world population older than 65 years, representing up to 2/3 of all patients with movement disorders throughout the world [3]
These effects suggest the role of oxidative stress in the pathogenesis of PD, and the use of drugs designed to decrease the neurodegenerative effects caused by free radicals displays great potential for the treatment of the disease [123]
Summary
Parkinson’s disease (PD) is considered cosmopolitan and makes no distinction between social classes or between races, affecting both men and women, especially in the age range between 55 and 65 years, but it tends to occur with greater frequency in men [1, 2]. It is estimated that this disorder affects approximately 1% of the world population older than 65 years, representing up to 2/3 of all patients with movement disorders throughout the world [3]. According to Silberman et al [4], the number of individuals older than 60 years has been increasing, as has life expectancy in developing countries. Along with health issues associated with an aging population, PD imposes a significant impact on the economic, social, and health structures of these countries [5]. It is estimated that by 2020, approximately 40 million people worldwide will develop motor disorders secondary to PD [2, 6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
